Foralumab
- Generic Name
- Foralumab
- Drug Type
- Biotech
- CAS Number
- 946415-64-1
- Unique Ingredient Identifier
- J43DL56H6M
- Background
Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Nasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis
Phase 2
Recruiting
- Conditions
- Non-Active Secondary Progressive Multiple Sclerosis
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 55
- Registration Number
- NCT06890923
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
- Conditions
- Non-Active Secondary Progressive Multiple Sclerosis
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT06802328
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Phase 2
Not yet recruiting
- Conditions
- DementiaAlzheimers DiseaseMild Cognitive Impairment Due to Alzheimer's Disease
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT06489548
- Locations
- 🇺🇸
Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts, United States
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Phase 2
Recruiting
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Other: Placebo
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 54
- Registration Number
- NCT06292923
- Locations
- 🇺🇸
University of Buffalo, Buffalo, New York, United States
🇺🇸Cornell Weill Medical Center, New York, New York, United States
🇺🇸Yale, North Haven, Connecticut, United States
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
Phase 1
Withdrawn
- Conditions
- Primary Progressive Multiple SclerosisSecondary Progressive Multiple SclerosisMultiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT05029609
A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT05028946
In-patient COVID-19 Study of Intranasal Foralumab
Phase 2
Withdrawn
- Conditions
- COVID-19 Lower Respiratory InfectionCovid19COVID-19 Respiratory Infection
- Interventions
- Other: Placebo
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT04983446
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
Phase 2
Withdrawn
- Conditions
- NAFLDNASH - Nonalcoholic SteatohepatitisT2DM (Type 2 Diabetes Mellitus)
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT03291249
NI-0401 in Patients With Acute Renal Allograft Rejection
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2009-06-09
- Lead Sponsor
- Light Chain Bioscience - Novimmune SA
- Target Recruit Count
- 12
- Registration Number
- NCT00805909
- Locations
- 🇫🇷
Hôpital Necker, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath